CAJ | 학술논문

目的:探讨急性冠脉综合征(ACS)患者血清中 sLOX-1、MMP-9水平变化,为临床判断冠状动脉粥样硬化(AS)斑块性质提供理伦依据.方法:选取2011年7月-2012年8月在本院行冠状动脉造影患者63例,男性34例,女性29例,平均年龄(62.7士9.6)岁.根据造影结果分为3组:AMI 组23例,UAP组20例,正常对照组20例.应用酶联免疫吸附试验(ELISA 法)检测血清 sLOX-1和 MMP-9水平.分别在入院时测定 sLOX-1、MMP-9水平,通过180d 的随访,观察比较远期心血管事件的发生率.结果:ACS 患者血清 sLOX-1、MMP-9水平明显高于正常对照组(P<0.05);AMI 组患者血清 sLOX-1、MMP-9水平高于 UAP 组患者比较差异有统计学意义(P<0.05).随访180d,高于均值 sLOX-1和 MMP-9水平组者180 d 再缺血事件发生率高(P<0.05).Kaplan-Meier 生存分析显示.高于均值 sLOX-1和 MMP-9水平组者180 d 预后的预测作用高于低于均值水平组者差异有统计学意义.结论: sLOX-1、MMP-9血清水平可作为判断 AS 斑块不稳定性的指标,并参与 AS 斑块由静止状态向活动状态转化继而斑块破裂的过程,其水平可能成为预测近期再缺血事件指标之一.
목적:탐토급성관맥종합정(ACS)환자혈청중 sLOX-1、MMP-9수평변화,위림상판단관상동맥죽양경화(AS)반괴성질제공리륜의거.방법:선취2011년7월-2012년8월재본원행관상동맥조영환자63례,남성34례,녀성29례,평균년령(62.7사9.6)세.근거조영결과분위3조:AMI 조23례,UAP조20례,정상대조조20례.응용매련면역흡부시험(ELISA 법)검측혈청 sLOX-1화 MMP-9수평.분별재입원시측정 sLOX-1、MMP-9수평,통과180d 적수방,관찰비교원기심혈관사건적발생솔.결과:ACS 환자혈청 sLOX-1、MMP-9수평명현고우정상대조조(P<0.05);AMI 조환자혈청 sLOX-1、MMP-9수평고우 UAP 조환자비교차이유통계학의의(P<0.05).수방180d,고우균치 sLOX-1화 MMP-9수평조자180 d 재결혈사건발생솔고(P<0.05).Kaplan-Meier 생존분석현시.고우균치 sLOX-1화 MMP-9수평조자180 d 예후적예측작용고우저우균치수평조자차이유통계학의의.결론: sLOX-1、MMP-9혈청수평가작위판단 AS 반괴불은정성적지표,병삼여 AS 반괴유정지상태향활동상태전화계이반괴파렬적과정,기수평가능성위예측근기재결혈사건지표지일.
Objective:To investigate the changes of serum soluble LOX-1 and MMP-9 levels in the Vulnerable plaque of coronary heart disease and provide theoretical evidence for judgement of the nature of coronary therosclerotic plaque. Methods: 63 patients who had undergone coronary angiography were divided into ACS group including 23 cases of acute myocardial infarction (AMI) and 20 cases of unstable angina (UAP) and normal control group(n=20). Using enzyme-linked immunosorbent test (ELISA) test, the levels of serum sLOX-1 and \MMP-1 were detected. The baseline materials and readmission because of AMI and ACS during 180days folow up were colected .According to different levels of sLOX-1 and MMP-9 And incidence of recurrent events were analysed.[Results]: The serum levels of sLox-1 and MMP-9 in patients in ACS were higher than those in control group(P<0.05):the serum level of sLox-1 and M M P-9 in patients with AMI was higher than that in UAP group(P<0.O5). Higher sLOX-1 and MMP-9 attributed to higher risk of recurrent evidence of 180 days (P<O.05). Concludes: The serum levels of sLox-1 and MMP-9 can be used to judge the nature of coronary atherosclerotic plaque; sLox-1 and ,MMP-9 and can accelerate the progress of unsteady of coronary atherosclerotic plaque and promote plaque rupture; the serum level of sLox-1 and MMP-9 may become important biochemical monitoring indicators about recurrent evidence